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Abstract 
Purpose: To evaluate the antiplatelet aggregation and cytotoxic potential of betulinic acid (BA), 
oleanolic acid (OA), maslinic acid (MA) and their derivatives (3-β-acetyloleanolic acid (OAA) and 3-β-
acetylbeutulinic (BAA) from medicinal plants. 
Methods: The compounds were characterized by nuclear magnetic resonance (NMR, both carbon 13 
and hydrogen 1) (NMR), infra-red (FTIR) and mass spectroscopy (MS). The platelet aggregation 
inhibitory activities of the compounds (1, 3, 5 and 10 mg/ml) were investigated separately on adenosine 
diphosphate (ADP) and thrombin-induced rat platelet aggregation. Cytotoxicity studies were carried out 
on human embryonic kidney (HEK293) and hepatocellular carcinoma (HEPG2) cell lines using 3, 4, 5-
dimethylthiazol-2-yl)-2-5-diphenyltetrazoliumbromide assay.  
Results: The compounds significantly (p < 0.05) inhibited platelet aggregation in a dose-dependent 
manner on thrombin and ADP agonist.  BAA/OAA showed the highest activity on both agonists with IC50 
of 2.86 and 3.05 mg/mL respectively. BAA/OAA also showed better antiplatelet activity than aspirin (IC50 
of 6.45 and 7.36 mg/mL, respectively).  In addition the compound (BA/OA, BAA/OAA and MA/OA) 
exhibited low cytotoxic effect on both HEK293 cells (IC50: 724.43, 269.08 and 407.89 mg/mL 
respectively) and HEPG2 (IC50: 585.38, 499.78 and 499.78 mg/mL, respectively). 
Conclusion: BAA/OAA demonstrate the best antiplatelet potential and low cytotoxicity of in all the tests, 
and therefore can serve as safer antiplatelet agents.  
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Abnormal platelet aggregation is instrumental to 
the pathogenesis of thromboembolic events such 
as stroke, deep venous thrombosis, heart attack 
and pulmonary embolism [1]. Endogenous 
agonists such as collagen, epinephrine, ADP, 
and thrombin induce platelet aggregation. These 
agonists trigger phospholipase (PLC) family that 
cleave phosphatidylinositol-4, 5- bisphoshate into 
inositol 1, 4, 5 bisphosphate (IP3) and 
diacylyglycerol (DG). The IP3 and DG initiate 
calcium influx and activation of protein kinase 
respectively [1]. Despite availability the anti-
platelet drugs, mortality rate associated with 
cardiovascular diseases is on the increase. Most 
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of the current used anti-platelet drugs are with 
undesirable side effects [2]. Therefore, there is 
need to search for alternative treatment from 
natural origin. 
 
Melaleuca braceteata belongs to Myrtaceae 
family and it is indigenous in Australia, commonly 
called golden bottle brush, punk and white cloud 
tree [3]. The essential oil from M. braceteata has 
been reported to possess antibacterial, 
antifungal, antiseptic, insecticide and eliminate 
genital wart [4]. 
 
Syzygium aromaticum (clove) belongs to 
Myrtaceae family and it is indigenous to 
Indonesia [5].  S. aromaticum is commonly used 
as nutritional spice [5]. S. aromaticum has been 
also demonstrated to possess antimicrobial, 
antiseptic, aphrodisiac, anti-emetic, anti-
inflammatory and carminative properties [5,6].  
 
Triterpenes possess wide spectrum of biological 
activities such as anti-inflammatory, anti-HIV, 
antimutagenic antimicrobial, antitumor and 
anticancer [7]. In this present study, the 
antiplatelet aggregation activity and cytotoxic 
effect of the mixture of BA/OA, BAA/OAA as well 






Unless otherwise stated, all reagents were 





Fresh leaves of Melaleuca braceteata var. 
revolution gold were collected in March, 2014 
from trees growing within the KwaDlangezwa 
campus of University of Zululand, South Africa. 
The plant was authenticated by Dr NR Ntuli of 
Department of Botany, University of Zululand. A 
voucher specimen (voucher number FO4) was 
deposited at the University Herbarium. 
Syzygium aromaticum (cloves) was purchased 
from spices market in Durban, South Africa and 
were authenticated by Mr. Pawn Porum of the 
Department of Botany, University of KwaZulu-
Natal, Westville campus with the voucher 
specimen (VN/004) which was deposited at the 
University of KwaZulu-Natal Herbarium. 
 
Extraction and isolation of BA/OA from 
Melaleuca bracetata var. revolution gold 
 
The method of Habila et al [8] was adopted with 
slight modification. Fresh leaves of M. braceteata 
(600 g) were dehumidified and extracted by 
maceration in ethyl acetate at room temperature 
(5 L x 3) for 72 h. The filtrate was concentrated 
with rotatory evaporator (40 oC) to yield 0.8 % of 
the crude extract. The crude extract was then 
defatted with n-hexane. A portion of the crude 
extract (6 g) was subjected to silica gel (60-120 
mesh) column chromatography (20 x 5.5 mm) 
using a gradient of n-hexane and ethylacetate 
(8:2 to 7:3) as the solvent system. A total of 77 
fractions of eluates (20 ml each) were collected 
and analyzed with thin layer chromatography.  
Fractions with the desired compounds monitored 
with TLC were combined and concentrated by 
rotatory evaporator. This was then recrystallized 
with methanol to form a white powder. Attempts 
to further separate the mixture of BA/OA were 
unsuccessful.  
 
Synthesis of BAA/OAA from BA/OA 
 
The method described by Andrine et al [9] was 
adopted. The mixture of BA/OA (2 g) isolated 
from M. braceteata var. revolution gold was 
dissolved in a solution containing a mixture of 
pyridine (10 ml) and acetic acid anhydride (12 
ml). This was refluxed for 8 h until a complete 
solution result. The reaction was terminated by 
the addition of distilled water (25 ml) and stirring 
for another 45 min. The synthesized compounds 
were rinsed with 12 % HCl to remove excess 
pyridine and dehumidified at room temperature. 
The compounds were further purified by silica gel 
(60 x 120 mesh) column chromatography (20 x 
5.5 mm), and eluted with a gradient of n-hexane 
and ethylacetate (8:2 to 7:3). Forty seven 
fractions of eluates (20 ml, each) was collected 
and analysed by TLC. Fractions with desired 
compounds were combined and concentrated 
using rotatory evaporator at 40 oC. The mixture 
of BAA/OAA was recrystallized with methanol 
and air-dried to give a white powder. 
 
Extraction and isolation of MA/OA from S. 
aromaticum (cloves) 
 
The method of Ibrahim et al [10] was used with 
slight modification. Buds of S. aromaticum (400 
g) were milled by an industrial blender. The 
milled samples were extracted with 
dichloromethane (2 L x 3) for 24 h on a lab com 
shaker (36 rpm, 37 oC) and filtered. The filtrate 
was concentrated with rotatory evaporator (40 
oC) to yield 2.0 % of the initial weight of plant 
samples.  The crude extract was de-fatted with n-
hexane and a portion (7 g) was subjected to 
silica gel (60-120 mm) column chromatography 
(20 x 5.5 mm) using n-hexane and ethyl acetate 
solvent system ranging from 9:1 to 8:2. Total 
fractions of (58) eluates (30 ml, each) were 
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collected and analyzed with TLC. Fractions 
containing desired compounds were combined 
and concentrated using rotatory evaporator (40 




Adult Sprague Dawley rats (220 – 250 g) of 
either sex were used. The animals were 
maintained under light condition (12/12 h 
light/dark), humidity (55 %), constant 
temperature (22 ± 2 oC) and had access to pellet 
feeds and safe drinking water. The experiments 
were approved (UZREC 171110-030 PGD 
2014/53) by Research Animal Ethic Committee 
(RAEC) of the University of Zululand and were 
conducted based on the guideline for the use of 
laboratory animals [11]. 
 
Plasma-rich platelet (PRP) 
 
Plasma-rich platelet (PRP) was prepared 
according to the method described by Mosa et al 
[12]. The animals were sacrificed by cervical 
dislocation and blood was collected from 
punctured heart with surgical needle (5 ml). 
 
The blood was transferred into a 15 ml test tube 
containing anticoagulant (acid–dextrose, 85 mM 
trisodium citrate, 83 mM dextrose and 21 mM 
citric acid). Plasma-rich platelet was obtained 
through series of centrifugation at 1200 rpm for 
15 min and 2200 rpm for 3 min consecutively. 
The supernatant was further centrifuged at 3200 
rpm for 15 min. The residue was re-suspended in 
washing buffer (5 ml, pH 6.5) while the 
supernatant was discarded and PRP were 
suspended in a small volume of suspending 
buffer (0.4 mM NaCl, 15 mM Tris-HCl, 5 mM 
glucose, pH 7.4). The platelets were diluted with 
resuspending buffer (1:10) and were further 
mixed with calcium chloride (0.4 ml:10 µl Cacl2). 
 
Anti-platelet aggregation studies 
 
Anti-platelet aggregation activities of the 
compounds were determined by the method 
described by Ibrahim et al [13] with slight 
modification. Anti-platelet aggregation activity 
was investigated using ADP (5 mM) and 
thrombin (5 µ/ml) as agonists. PRP (100 µl) were 
pipetted into 96 wells plate and pre-incubated for 
6 minutes at 40 oC with various concentration (1, 
3, 5 and 10 mg/ml) of the compounds. Platelet 
aggregation was then induced with separate 
agonists (20 µl). Anti-platelet aggregation 
activities of the compounds were measured by 
Bioteck plate and absorbance read at 415 nm. 
Aspirin served as the positive control while 
DMSO (1 %) served as a negative control. 
Antiplatelet aggregation activity was calculated 
by the formula. Inhibition % = Ao – A1/ Ao x 100 
(where Ao is mean slope of control while A1 is 
mean slope of tested compound). The value of 





The cytotoxicity of the compounds were 
determined by MTT (3, 4, 5-dimethylthiazol-2-yl)-
2-5-diphenyltetrazoliumbromide) assay described 
by Mosaman [14]. Human hepatocellular 
carcinoma (HepG2) and human embryonic 
kidney (HEK293) cells lines were used for this 
assay.  The cell line in the tissue culture was 
grown in flasks (25 cm2) and trypsinized. This 
was then pipetted into 96 well plate at specific 
seeding densities and incubated for 24 h at 37 
°C.  The medium was removed and replaced 
with fresh medium (MEM + Glutmax + 
antibiotics). The isolated compounds (50 – 350 
μl/ml) were added in triplicate and incubated for 
4 h at 37 oC. The medium was again removed 
and replaced with a complete medium (MEM + 
Glutmax + antibiotics + 10 % fetal bovine serum). 
This was incubated for 48 h at 37 oC for MTT 
assay. The compounds’ cytotoxic were evaluated 
by regression analysis using QED statistics 
program and IC50 values from the linear equation 




The experiments were carried out in triplicate 
and data expressed as mean ± standard 
deviation (SD). One-way analysis of variance 
(ANOVA) and post-hoc Dunnett’s test were used 
to analyze the results using Graphpad prism 
software (version 5.03). Statistical significance 






Sample 1 (BA/OA) 
 
BA/OA (Figure 1) white powder; mp 290–292 oC; 
IR (KBr) vmax 3553, 2990, 1739, 1453, 1374, 
1239, 1087 cm-1; m/z (ESI) 456 (M+, BA/OA); δH 
(400 MHz, CDCl3 and CH3OD): 4.96 (s, 1H), 4.44 
(1H, s), 4.43 (1H, s), 3.11, 2.73, 1.98, 1.43, 1.29, 
0.79-1.24 (21H, m); δC (100 MHz, CDCl3 and 
CH3OD): see Table 1. 
 
Sample 2 (BAA/OAA) 
 
BAA/OAA (Figure 2) white powder; mp 297-299 
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Figure 1: Structure of isolated compounds 
 
oC; IR (KBr) vmax 2990, 1739, 1451, 1373, 1235, 
1045 cm-1; m/z (ESI) 498 (M+, BAA) m/z (ESI) 
499 (M+, OAA); δH (400 MHz, CDCl3): 5.18 (s, 
1H), 4.60 (1H, s), 4.47 (1H, s), 4.34 (1H, s), 2.88, 
2.11, 1.95, 1.93, 1.81, 1.57, 0.72 – 1.49 (m); δC 
(100 MHz, CDCl3): see Table 1. 
 
Sample 3 (MA/OA) 
 
The compounds’ identification has been reported 
in our previous research works [12]. 
 
The isolation of sample 1 and the formation of 
sample 2 were confirmed by 1H, 13C NMR and IR 
spectroscopy. The presence of hydroxyl groups 
in these compounds was indicated by the 
appearance of an absorption band around 3553 
cm-1 in the IR Spectra.  The C-H stretching 
frequencies were observed around 2990 cm-1, 
also the bands that are characteristics of the 
presence of carboxylic acid in a molecule were 
observed around 1739 cm-1  [15]. The IH NMR 
spectra of samples 1 and 2 both revealed various 
peak corresponding to the methyl groups at 
around 0.72-1.49 ppm and terminal methylene 
protons at 4.34–5.18 ppm. 
 
Further confirmation for the isolation of sample 1 
and formation of sample 2 was provided by 13C 
NMR spectroscopy. The 13C NMR spectra of 
samples 1 and 2 showed that they were 
mixtures. This is as a result of the appearance of 
60 carbons signals in 13C NMR spectrum of 
sample 1 (30 each for BA and OA as assigned in 
Table 1) and 64 carbons signals in 13C NMR 
spectrum of sample 2 (32 each for BAA and OAA 
as assigned in Table 1) which agree with the 
reported data for related compounds [8,16]. For 
sample 2 the appearances of four additional 
carbons in the 13C spectrum (two each for BAA 
and OAA) assigned as C-31 and C-32 
respectively (Table 1) further confirmed the 
formation of BAA/OAA. Further evidence for the 
isolation and formation of BA/OA and BAA/OAA 
was provided by the ESI-MS spectra which 
showed intense molecular ions corresponding to 
M+. 
 
Anti-platelet aggregation  
 
The compounds significantly (p < 0.05) inhibit 
platelet aggregation induced by ADP in a dose- 
dependent manner (Figure 3a). BA/OA and 
BAA/OAA exhibited the highest anti-platelet 
aggregation activities. BAA/OAA mixture 
displayed optimal anti-platelet aggregation 
activity at 5 mg/ml.  BA/OA and BAA/OAA 
showed better IC50 value of 3.05 mg/ml and 3.25 
mg/ml respectively when compared with aspirin 
(IC50 value of 7.36 mg/ml) the positive control 
(Table 2). Similarly, the compounds dose-
dependent significantly inhibit platelets 
aggregation in thrombin induced platelet 
aggregation (Figure 3b). BAA/OAA possessed 
the highest anti-platelet aggregation activity. 
 
  Figure 2: Schematic representation of the synthesis of BAA/OAA from BA/OA 
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Table 1: 13C-NMR (100 MHz) spectral data for sample 1 and 2 
 
Position  Sample 1 Sample 2 
1 38.5 (BA)   38.7 (OA)  (CH2) 38.1 (BAA)     38.2 (OAA) 
2 27.3 (BA)   29.2 (OA)  (CH2) 27.7 (BAA)     29.5 (OAA) 
3 78.2 (BA)   78.2 (OA)  (CH) 81.2 (BAA)     81.2 (OAA) 
4 38.7 (BA)   40.2 (OA)  (C) 38.2 (BAA)    40.5 (OAA) 
5 55.0 (BA)   55.9 (OA)  (CH) 55.1 (BAA)     55.2 (OAA) 
6 17.8 (BA)   18.6 (OA)  (CH2) 18.0 (BAA)     19.0 (OAA) 
7 33.9 (BA)   32.6 (OA)  (CH2) 34.0 (BAA)     32.1 (OAA) 
8 40.2 (BA)   39.0 (OA)  (C) 40.5 (BAA)     38.2 (OAA) 
9 50.1 (BA)   48.9 (OA)  (CH) 50.3 (BAA)     49.9 (OAA) 
10 36.7 (BA)   37.8 (OA)  (C) 37.0 (BAA)     38.1 (OAA) 
11 20.5 (BA)   23.7 (OA)  (CH2) 20.7 (BAA)      23.5 (OAA) 
12 25.1 (BA)   125.10 (OA)  (CH2) 25.3 (BAA)      125.0 (OAA) 
13 37.9 (BA)   137.8 (OA)  (CH) 37.6 (BAA)      143.0 (OAA) 
14 42.0 (BA)   42.1 (OA)  (C) 42.2 (BAA)      42.3 (OAA) 
15 30.2(BA)   27.6(OA)  (CH2) 30.4(BAA)       27.7 (OAA) 
16 31.8 (BA)   23.7 (OA)  (CH2) 32.1 (BAA)      23.5 (OAA) 
17 55.8 (BA)   46.7 (OA)  (C) 56.0 (BAA)      46.8 (OAA) 
18 46.6 (BA)   42.0 (OA)  (CH) 46.8 (BAA)      42.2 (OAA) 
19 48.8 (BA)   46.7 (OA)  (CH) 49.0 (BAA)      46.8 (OAA) 
20 150.2 (BA)  31.8 (OA)  (C) 150.5 (BAA)     32.1 (OAA) 
21 29.2 (BA)   33.9 (OA)  (CH2) 29.5 (BAA)       34.0 (OAA) 
22 36.5 (BA)   32.6 (OA)  (CH2) 36.9 (BAA)       32.1 (OAA) 
23 27.5 (BA)   29.2 (OA)  (CH3) 27.7 (BAA)       29.5 (OAA) 
24 14.8 (BA)   16.4 (OA)  (CH3) 14.4 (BAA)       16.2 (OAA) 
25 15.1 (BA)   15.6 (OA)  (CH3) 15.7 (BAA)       15.9 (OAA) 
26 15.3 (BA)   17.8 (OA)  (CH3) 15.6 (BAA)       18.0(OAA) 
27 14.1 (BA)   26.2 (OA)  (CH3) 14.4 (BAA)       25.3 (OAA) 
28 178.6 (BA)  180.2 (OA)  (C) 178.9 (BAA)     178.9 (OAA) 
29 18.6 (BA)    33.9 (OA)  (CH3) 19.0(BAA)        34.0 (OAA) 
30 108.9 (BA)   23.7 (OA)  (CH2) 109.3 (BAA)     23.5 (OAA) 
31 - 171.6 (BAA)    171.6 (OAA)    (C) 
32 - 23.5 (BAA)      23.5 (OAA)      (CH3) 
 Data reported in ppm. BA, OA, BAA and OAA 
 
Table 2: IC50 values of the compounds on platelet 
aggregation inhibition 
                 
Compound IC50 (mg/ml) 
 Thrombin ADP 
BA/OA                                              
BAA/OAA                                       
MA/OA                                             










BAA/OAA also showed better IC50 value of 2.86 
mg/ml than BA/OA and MA/OA mixture with IC50 
value of 9.71 mg/mL, 9.30 mg/ml respectively. 
BAA/OAA (IC50 value of 2.86 mg/ml) was 
observed to possess twice the antiplatelet activity 




The result of cytotoxic assay revealed that all the 
compounds displayed poor cytotoxic effects on 
HEK293 and HEPG2 cells (Table 3). The 
compounds also showed better cytotoxic effects 
on HEPG2 than HEK293 cells, with BAA/OAA 
showing highest cytotoxic effect. 
 
Table 3: IC50 (µg/ml) of BA/OA, BAA/OAA and MA/OA 
acid on HEK293 and HEPG2 cells 
 
Compound IC50 (µg/ml) 
 
BA/OA                                  
BAA/OAA                               
MA/OA                        










Platelet aggregation plays important role in 
thrombus formation [1]. Therefore, targeting 
abnormal platelet activation may be a promising 
approach to reduce cardiovascular mortality. 
Medicinal plants are currently the source of 
diverse bioactive compounds which are used for 
treatment of diseases. The multi-therapeutic 
properties of plant-derived triterpenes have made 
them the potential candidates for synthesis of 
new drugs. The present study revealed that the 
plant-derived triterpenes and derivatives possess 
anti-platelet aggregation activities regardless of 
the agonists. Anti-platelet aggregation activities 
of some triterpenes have previously been 
reported [17,18]. 
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Figure 3: Percentage Inhibitory activity of (a) ADP induced by platelet aggregation. (b) Thrombin induced by 
platelet aggregation. Data expressed as mean ± SD. Values of different letters in graph are significant (p < 0.05). 
The anti-platelet aggregation activity of BA/OA 
mixture isolated from the leaves of Callisteum 
viminalis has also been reported, and further 
separation of BA/OA mixture using open column 
silica gel chromatography has been unsuccessful 
[13]. The highest antiplatelet aggregation activity 
of BAA/OAA mixture could be attributed to the 
modification of hydroxyl moiety at C3 position 
with acetyl group. Targeting of carbon positions 3 
and 28 of compounds are the new 
pharmacophores to enhance biological activities 
[19].  It is worth noting that aspirin, a potent 
antithrombin agent has acetyl moiety as its major 
functional group [20]. To the best of our 
knowledge, this is the first time the BAA/OAA 
mixture was investigated as antiplatelet 
aggregation agent. 
 
In the search for potent and clinically safe 
antiplatelet drugs, there is need to evaluate their 
toxicities and safety margins [10]. The American 
National Cancer Institute guidelines consider 
compounds with IC50 < 30 µg/ml as cytotoxic 
[21]. The present study revealed that the 
compounds possessed weak cytotoxic properties 
in Table 3 on both normal cells (HEK293) and 
cancerous cell (HEPG2). This is contrary to 
previous reports of some triterpenes with strong 
cytotoxic effects [22,23]. Despite the weak 
cytotoxic effect of the compounds, they displayed 
better cytotoxic effects on HEPG2 than HEK293. 
This implies that the compounds could inhibit 
proliferation of cancer cell. Betulinic acid has 
previously been reported to selectively inhibit 
tumour cells [24]. Betulinic acid and derivatives 
isolated from Melaleuca cajuput have also been 
reported to selectively inhibit myeloid leukemia 




This study reveals that the test compounds 
possess antiplatelet potential regardless of the 
agonists. Structural modifications of the 
compounds further enhances their activities, but 
reduced cytotoxic effects on normal cell line. 
Therefore, these compounds can serve as 
candidates for safer antiplatelet agents. 
However, there is need to ascertain the 







The authors thank the University of Zululand 
Research Committee for her financial support. 
 
Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 




1. Dickneite G, Seiffe D, Diehl KH, Rogers M, Czech J. 
Pharmacological characterization on a new 4-
amidinophenyl-alanine thrombin-inhibitor (CRC220). 
Thromb Res 1995; 77: 357-368.  
Osunsanmi et al 
Trop J Pharm Res, August 2016; 15(8): 1619  
 
2. Armani S, Harnafi H, Gadi D, Mekhfi H, Legssyer A, Aziz 
M, Martin-Nizard F, Bosca L. Vaso-relaxant and anti-
platelet aggregation effects of aqueous Ocimum 
basilicum   extracts. J Ethnopharmacol 2009; 125: 157- 
162. 
3. Craven LA and Lepschi BJ. Enumeration of the species 
and infraspecific taxa of Melaleuca (Myrtaceae) 
occurring in Australia and Tasmania. Austral Syst Bot 
1999; 12: 863-867. 
4. Oliva B, Piccirilli E, Ceddia T, Ponteri E, Aureli P,  Ferrini 
AM. "Antimycotic activity of Melaleuca alternifolia 
essential oil and its major components". Lett Appl 
Microbiol 2003; 37(2): 185-187. 
5. Debjit BKP, Sampath K, Akhilesh Y, Shweta S, Shravan 
P, Amit SD. Recent Trends in Indian Traditional Herbs 
Syzygium aromaticum and its Health Benefits. J 
Pharmacogn Phytochem 2012; 1(1): 13-22.  
6. Jirovetz L, Buchbauer G. Chemical Composition and 
Antioxidant Properties of Clove Leaf Essential Oils.  J 
Agric Food Chem 2006; 54: 6303‐6307. 
7. Qian K, Nakagawa-Goto K, Yu D, Morris-Natschke LM, 
Nitz. TJ, Kilgore N, Allaway GP, Lee KH. Anti-AIDS 
agents 73: Structure-activity relationship study and 
asymmetric synthesis of 3-Omonomethylsuccinyl- 
betulinic acid derivatives. Bioorg Med Chem Lett 2007; 
17(23): 6553-6557. 
8. Habila AJ, Habila JD, Shode FO, Opoku AR, Atawodi SE, 
Umar IA. Inhibitory effect of betulinic acid and 3β- 
acetoxybetulinic acid on rat platelet aggregation.  Afr J 
Pharm Pharmacol 2013; 7(43): 2881-2886. 
9. Adrine MI, Gloria NS, Laura NC, Miriam SM, Myna N, 
Pascal SG, Célia RS. Simone, CB. Synthesis and 
Antiplasmodial Activity of Betulinic Acid and Ursolic Acid 
Analogues. Molecules 2012; 17(10): 12003-12014. 
10. Ibrahim G, Abdurahman EM, Ibrahim H, Ibrahim NDG 
and Yaro AH. Toxicity and anti-inflammatory activity of 
Vernonia amygdalina Del. (Asteraceae) ethanol leaf 
extract. Chem Class J 2007; 4: 47-50. 
11. National Institute of Health, USA. Public health service 
policy on human care and use of laboratory animals; 
2002. 
12. Mosa RA, Oyedeji OA, Shode  FO, Singh M, Opoku AR. 
Triterpenes from the stem bark of Protorhus longifolia 
exhibit anti-platelet aggregation activity. Afr J Pharm 
Pharmacol 2011; 5(24): 2698-2714. 
13. Ibrahim T, Babalola R, Shode OS, Adelakun EA, Opoku 
AR and Rebamang AM. Platelet-Aggregation Inhibitory 
activity of oleanolic acid, ursolic acid, betulinic acid and 
maslinic acid. J Pharmacog Phytochem 2013; 1(6): 13-
17 
14. Mosaman T. Rapid colorimetric assay for cellular growth 
and survival: Application to proliferation and cytotoxicity 
assays.  J Immunol Methods 1983; 65(1-2):  55-63. 
15. Mahato SB, Kundu AP. 13C NMR Spectra of pentacyclic 
triterpentenoids-A compilation and Salient Features. 
Phytochem 1994; 37(6): 1517-1575. 
16. Seebacher W, Simic N, Weis R, Saf R. and Kunert O.  
Complete assignments of 1H and 13C NMR resonances 
of oleanolic acid, 18α-oleanolic acid, ursolic acid and 11-
oxo derivatives. Magn Reson Chem 2003; 41: 636-638. 
17. Habila JD, Shode FO, Opoku AR. Triterpenoids from 
Eucalyptus grandis Hill ex Maiden inhibits platelet 
aggregation. Afr J Microbiol Res 2011; 5(26): 4646- 4 
651. 
18. Tzakos AG, Kontogianni VG, Tsoumani M, Kyriakou E, 
Hwa J, Rodrigues FA, Tselepis AD. Exploration of the 
antiplatelet activity profile of betulinic acid on human 
platelets. J Agric Food Chem 2012; 60(28): 6977-83. 
19. Ban HS, Minegishi H, Shimizuk K, Maruyama M, Yasui Y, 
Nakamura H. Discovery of carbrances as inducers of 
20S proteasome activity. Chem. Med Chem 2010; 
5:1236-12 
20. Undas, A, Brummei-Ziedins KE, Mann KG. 
Antithrombotic properties of aspirin and resistance to 
aspirin: beyond strictly antiplatelet action. Blood 2007; 
15: 109 (6): 2285-2292  
21. Suffness M, Pezzuto JM. Assays related to cancer drug 
discovery. In Methods in Plant Biochemistry: Assays for 
Bioactivity; Hostettman, K., Ed.  Academic Press: 
London, UK 1990; pp 1-7. 
22. Lee HS, Kim SD, Lee WM, Endale M, Kamruzzaman SM, 
Oh WJ, Cho JY, Kim SK, Cho HJ, Park HJ, Rhee MH. A 
noble function of elevated CAMP-induced VASP, and 
decreased ERK2/JNK1 phosphorylations. Eur J 
Pharmacol 2010; 627(1-3): 85-91. 
23. Peteros NP and Uy MM. Antioxidant and cytotoxic 
activities and phytochemical screening of four Philippine 
medicinal plants. J Med Plants Res 2010; 4(5): 407-414. 
24. Pisha E, Chai H., Lee, I.S., et al., Discovery of betulinic 
acid as a selective inhibitor of human melanoma that 
functions by induction of apoptosis. Nat Med 1995; 
1(10): 1046- 51. 
25. Faujan NH, Alitheen NB, Yeap SK, Ali AM, Muhajir AH, 
Ahmad FBH. Cytotoxic effect of betulinic acid and 
betulinic acid acetate isolated from Melaleuca cajuput 
on human myeloid leukemia (HL-60) cell line. Afr J 
Biotechnol 2010; 9(38): 6387-6396. 
 
